I believe that outside the U.S. This becomes more important for the purpose of
the glaucoma application available there. Once the glaucoma package opens up
state side it will become a part of the protocol as well.
Kindest regards
Joey Hatfield
On Apr 24, 2015, at 11:34 AM, Paula Morris <paula.morris@xxxxxxxxxxxx> wrote:
Hello colleagues,
I have received an inquiry from the UK about how often Spectralis users in
the US enter the c-curve information when imaging clinical patients, not just
in clinical trials.
Thanks so much for sharing,
P
